SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

An industry observers reported identification of a POET optical engine at Foxconns Hon Hai Tech Day has traders debating whether it signals renewed progress in the existing FIT collaboration. Bulls see it as third-party validation, while skeptics say a demo or ecosystem display does not confirm production shipments, purchase orders, or a new company announcement.

OFFICIAL TRUMP (TRUMP) is a cryptocurrency and operates on the Solana platform. OFFICIAL TRUMP has a current supply of 999,998,809.831273 with 281,866,746.118905 in circulation. The last known price of OFFICIAL TRUMP is 1.73532194 USD and is up 9.97 over the last 24 hours. It is currently trading on 744 active market(s) with $259,407,006.57 traded over the last 24 hours. More information can be found at https://gettrumpmemes.com/.

Trump For President

A rebound in the TRUMP meme coin has prompted speculative calls for a pump or short squeeze, while the dominant discussion remains bearish: traders call it a pump-and-dump and point to steep losses among holders. Some remain bullish or say they are accumulating, but no specific confirmed catalyst for the move is apparent.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLakes pending FDA decision on whether to accept its sonelokimab application for hidradenitis suppurativaand the review timeline, including possible priority reviewis the main focus. Traders are divided between optimism about the drug and regulatory progress and concern about approval risk, weak share performance, and the costs of commercializing without a partner or buyout.

Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which engages in the development of novel therapies for the management of central nervous system disorders. Its portfolio consists of Products Overview and Pipeline Overview. The Products Overview includes Auvelity and Sunosi. The Pipeline Overview refers to AXS-05, AXS-07, AXS-12, and AXS-14. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY.

Axsome Therapeutics Inc

AXSM is drawing attention ahead of its Q3 results, with investors focused on Auvelitys growthespecially uptake for Alzheimers agitationand whether sales can support a path to profitability. The sharp share-price decline and managements limited recent commentary have intensified the debate: bulls say prescriptions may be understated by sampling and long-term-care channels, while skeptics question the pace of adoption, spending and commercial execution.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

A breakout to fresh 52-week highs ahead of expected Q3 results has put TGTX in focus, with traders watching BRIUMVIs sales momentum and guidance. Buyout and short-squeeze theories are also circulating, but remain speculation rather than confirmed catalysts.

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, George Damis Yancopoulos, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.

Regeneron Pharmaceuticals, Inc.

Regenerons strong third-quarter results, which beat expectations on growth led by Dupixent and Eylea HD, have driven a sharp share-price breakout. Traders are largely celebrating the report and bullish options activity, while some note that declining legacy Eylea sales remain a risk to watch.

Ouster, Inc. engages in the provision of high resolution digital lidar sensors that offer advanced 3D vision to machinery, vehicles, robots, and fixed infrastructure assets. The company was founded by Angus Pacala and Mark Frichtl on June 30, 2015 and is headquartered in San Francisco, CA.

Ouster Inc - Ordinary Shares - Class A

OUST is drawing attention amid a sharp, volatile pullback that traders link to weakness in growth and AI stocks, with Q3 earnings expectations adding uncertainty. The community is split between buying the dip on Ousters lidar and Physical AI opportunity and warning that shares could fall further.

AppLovin Corp. engages in the development and operation of a mobile marketing platform. It offers AppDiscovery, MAX, Adjust, and SparkLabs. Its software-based platform caters to mobile application developers to improve the marketing and monetization of applications. The company was founded by Andrew Karam, John Krystynak, and Adam Foroughi in 2011 and is headquartered in Palo Alto, CA.

Applovin Corp - Ordinary Shares - Class A

Applovin Corp

AppLovins sharp, sustained selloff is the dominant topic, with traders debating whether broader tech weakness, concerns about ad-market growth and analyst downgrades are weighing on the stock ahead of earnings. Bulls view the decline as disconnected from the companys growth and profitability, while bears worry about further downside and a weak earnings reaction.

Cava Group, Inc. is a holding company, which engages in the category-defining Mediterranean fast-casual restaurant brand, bringing together healthful food and bold, satisfying flavors at scale. It operates through the following segments: CAVA and CAVA Foods. The CAVA segment includes the operations of all company-owned CAVA restaurants. The CAVA Foods segment includes the production of dips and spreads used in CAVA restaurants as well as sales from the consumer-packaged goods (CPG) business. The company was founded by Brett Schulman, Ike Grigoropoulus, Dimitri Moshovitis, and Theodore Xenohristos in 2010 and is headquartered in Washington, DC.

Cava Group Inc

CAVA Group Inc

CAVAs stronger-than-expected quarterly results, including solid same-store sales and guest-traffic growth, fueled a sharp rebound and revived discussion of its store-expansion runway. Bulls see continued growth potential, while skeptics point to the stocks high valuation and pressure on restaurant spending.

Arista Networks, Inc. engages in the development, marketing, and sale of cloud networking solutions. Its solutions include EOS, a set of network applications, and Gigabit Ethernet switching and routing platforms. Its product categories include core, cognitive adjacencies, and cognitive networks. The company was founded by Andreas Bechtolsheim, David Cheriton, and Kenneth Duda in November 2004 and is headquartered in Santa Clara, CA.

Arista Networks Inc

A sharp pullback after a strong run is driving discussion, with traders weighing profit-taking and broader weakness in AI-infrastructure stocks against the upcoming earnings report. Bulls see the decline as a buying opportunity given Aristas role in AI data-center networking, while others worry about further downside and whether spending expectations are too high.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Does CSX Stock's Q3 Earnings Beat Justify a Buy Decision Today?

We assess the investment worthiness of CSX stock post its third-quarter 2026 earnings release.

Is CSX (CSX) Stock Outpacing Its Transportation Peers This Year?

Here is how CSX (CSX) and Knight-Swift Transportation Holdings (KNX) have performed compared to their sector so far this year.

$1000 Invested In CSX 15 Years Ago Would Be Worth This Much Today

CSX (NASDAQ:CSX) has outperformed the market over the past 15 years by 1.0% on an annualized basis producing an average annual return of 14.03%. Currently, CSX has a market capitalization of $95.72 billion.
Buyingread more...

CSX Analysts Boost Their Forecasts Following Upbeat Q3 Earnings

CSX beat Q3 estimates with $4.02B revenue and 57? EPS; shares rose 6.7% as analysts raised price targets.read more...

CSX Q3 Earnings Beat Estimates on Higher Volumes and Pricing

CSX beats Q3 earnings estimates as higher freight volumes, improved pricing and revenue growth boost profits and margins despite surging fuel expenses.

CSX: 3 Key Takeaways for Long-Term Investors

Key PointsCSX increased third-quarter volume by 5% and cut nonfuel costs by 3...

CSX (CSX) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates

The headline numbers for CSX (CSX) give insight into how the company performed in the quarter ended September 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

CSX (CSX) Q3 Earnings and Revenues Beat Estimates

CSX (CSX) delivered earnings and revenue surprises of +9.62% and +1.66%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?

CSX Corp Q3 26 Earnings Conference Call At 4:30 PM ET

(RTTNews) - CSX Corp (CSX) will host a conference call at 4:30 PM ET on October 21, 2026, to discuss Q3 26 earnings results...

$100 Invested In CSX 10 Years Ago Would Be Worth This Much Today

CSX (NASDAQ:CSX) has outperformed the market over the past 10 years by 3.06% on an annualized basis producing an average annual return of 16.7%. Currently, CSX has a market capitalization of $88.70 billion.
Buying $100read more...

CSX Corp. engages in the provision of rail-based freight transportation services. Its services include rail service, the transport of intermodal containers and trailers, rail-to-truck transfers, and bulk commodity operations. It operates through Rail and Trucking segments. The Rail segment provides rail-based transportation services including traditional rail service and the transport of intermodal containers. The Trucking segment relates to quality carriers. The company was founded in 1827 and is headquartered in Jacksonville, FL.

CSX Corp.

Why Did IMAX, JPM, CSX Stocks Surge To 52-Week Highs Last Week?

Equity

Neutral Sentiment

<ul class="summary-bullets"><li>IMAX stock jumped to a 52-week high of $45.88 after it received a series of price target hikes on Friday.</li><li>JPM stock jumped to a 52-week high of $353.37 on Friday, extending to four consecutive sessions in the green.&nbsp;</li><li>CSX stock jumped to an annual high of $53.40 on Friday, bolstering its weekly gains to 4.89%, the best since February.&nbsp;</li></ul><p>Shares of IMAX Corp. (IMAX), JPMorgan Chase &amp; Co. (JPM), and CSX Corp. (CSX) surged to 52-week highs on Friday amid a series of Wall Street price target hikes and continuing momentum from earnings results.&nbsp;</p><p>IMAX stock closed down about 1.3% after jumping to an annual high amid Wall Street optimism, while JPM stock and CSX stock gained nearly 1% each at close.&nbsp;</p><h2 class="st-heading-2"><strong>Wall Street Turns Optimistic On IMAX On Q2 Beat</strong></h2><p><a href="https://stocktwits.com/symbol/IMAX">IMAX stock</a> jumped to a 52-week high of $45.88 after it received a series of price target hikes on Friday following its strong second-quarter (Q2) earnings results.&nbsp;</p><p>The theatre company posted revenue growth of 12.2% year-over-year to $102.8 million, while adjusted earnings per share jumped 65% to a record $0.43, topping analysts' estimates.&nbsp;</p><p>IMAX said that it delivered its strongest Q2 global box office since 2019, generating $285 million as international markets outside China drove 24% growth. The company also reported its highest quarterly theatre installations in a decade and said strong early demand for Christopher Nolan's&nbsp;The Odyssey, including record opening weekend results and about $60 million in presales, positions it for a robust second half.&nbsp;</p><p>Multiple analysts raised price targets on the company, summarized as below:&nbsp;</p><div><figure class="table"><table class="ck-table-resized"><colgroup><col><col><col><col></colgroup><tbody><tr><td>Firm</td><td>Old Price Target</td><td>New Price Target</td><td>Potential Upside From Last Close</td></tr><tr><td>Wells Fargo</td><td>$41</td><td>$45</td><td>3.73%</td></tr><tr><td>JPMorgan</td><td>$47</td><td>$50</td><td>15.26%</td></tr><tr><td>Rosenblatt</td><td>$47</td><td>$50</td><td>15.26%</td></tr><tr><td>Wedbush</td><td>$46</td><td>$54</td><td>24.48%</td></tr><tr><td>B. Riley</td><td>$48</td><td>$52</td><td>19.87%</td></tr><tr><td>Barrington</td><td>$46</td><td>$50</td><td>15.26%</td></tr><tr><td>Roth Capital</td><td>$48</td><td>$50</td><td>15.26%</td></tr></tbody></table></figure></div><p>&nbsp;</p><p>On Stocktwits, retail sentiment was ‘bullish’ at the time of writing. IMAX shares have gained more than 20% this year.&nbsp;</p><h2 class="st-heading-2"><strong>JPMorgan Gains On Continued Momentum From Strong Quarterly Results</strong></h2><p><a href="https://stocktwits.com/symbol/JPM">JPM stock</a> jumped to a 52-week high of $353.37 on Friday, extending to four consecutive sessions in the green.&nbsp;</p><p>Earlier this month, the bank posted strong quarterly&nbsp;<a href="https://stocktwits.com/news-articles/default/5/jamie-dimon-warns-risk-shifting-below-surface-tectonic-platers-war-inflation/cZZbHLmR7pj">results</a>, declaring earnings per share (EPS) of $7.7 on revenue of $57.35 billion, much ahead of Wall Street expectations.&nbsp;</p><p>It also reported its best quarter in terms of trading revenue, jumping 35% year-on-year to $12.1 billion. Investment banking fees came in at $3.3 billion, growing 30% in the quarter and rising to the highest level since 2021.&nbsp;</p><p>JPMorgan CEO Jamie Dimon said every business segment posted record results, adding that market sentiment remains supportive of continued activity.</p><p>JPM stock is up more than 8.5% this year, while retail sentiment has stayed ‘bearish’ over the past 24 hours.&nbsp;</p><h2 class="st-heading-2"><strong>CSX Stock Gains On Price Target Hikes</strong></h2><p><a href="https://stocktwits.com/symbol/CSX">CSX stock</a> jumped to an annual high of $53.40 on Friday, bolstering its weekly gains to 4.89%, the best since February.&nbsp;</p><p>The company’s share prices climbed higher after it posted solid Q2 numbers, with revenue rising 10% year-on-year to a record $3.94 billion and diluted earnings per share increasing 23% to $0.54, beating Wall Street estimates.&nbsp;</p><p>Net income climbed to $1 billion, while operating income rose 17% and the operating margin expanded 240 basis points to 38.3%, reflecting improved profitability.</p><p>Citi raised the price target on CSX to $54 from $53 and maintained a Neutral rating on the shares, implying an upside of about 1.5% from its last close. Meanwhile, Deutsche Bank raised the price target on the company to $59 from $48 and kept a ‘Buy’ rating on the shares, implying an upside of nearly 11%.&nbsp;</p><p>CSX shares have gained more than 46% in 2026. Meanwhile, retail sentiment was ‘bullish’ at the time of writing.&nbsp;</p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p>

JPMorgan Chase Warns Of Business 'Exodus' From NYC As Mayor Mamdani Pushes For Tax Hikes. (Photo by Zamek/VIEWpress)

52 week high, top gainers, 52 week high stocks, IMAX stock, JPM stock, CSX stock, IMAX earnings, JPM earnings, CSX earnings

IMAX, JPMorgan Chase and CSX jumped to 52-week highs on Friday amid growing Wall Street optimism after all companies posted strong Q2 results last week. 

Imax Corp

JPMorgan Chase & Co

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$51.99
Prev Close	$52.24
Open	$52.31
Dividend Yield	1.43%
50-Day Moving Average	$48.86
Beta	0.63
Avg. Volume	10.78M
PE Ratio	26.97

52-Week High	$53.60
52-Week Low	$33.63
Market Capitalization	$95.84B
EPS (Annual)	$1.54
Price to Book	6.67
Revenue Per Employee	$612,695.65

Feed

News

Sentiment

Earnings

Fundamentals

Info

CSX Fundamentals